Zobrazeno 1 - 10
of 93
pro vyhledávání: '"Pei-yuan Su"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Vitamin D deficiency is common in patients with inflammatory bowel disease (IBD). In this study, we aimed to evaluate the prevalence and risk factors of vitamin D deficiency in a Taiwanese IBD cohort. Vitamin D levels were checked in adult p
Externí odkaz:
https://doaj.org/article/2a0e3c6aa6e2468dac47b729350e953a
Autor:
Ting-Chun Chen, Shun-Wen Hsiao, Yang-Yuan Chen, Hsu-Heng Yen, Wei-Wen Su, Yu-Chun Hsu, Siou-Ping Huang, Pei-Yuan Su
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Due to the comprehensive hepatitis B virus vaccination program in Taiwan since 1986, the development of antiviral therapy for chronic hepatitis B and chronic hepatitis C infection and covered by National health insurance. Besides, the increa
Externí odkaz:
https://doaj.org/article/df7fc9c49cb341978fa1fd0fc622f254
Publikováno v:
BMC Gastroenterology, Vol 22, Iss 1, Pp 1-6 (2022)
Abstract Background/Aims Entecavir (ETV) can suppress chronic hepatitis B (CHB) virus replication as a standard of treatment drugs. For the treatment of CHB, affordable generic drugs may be more widely used in developing and undeveloped countries. Ho
Externí odkaz:
https://doaj.org/article/181b70e840894e1b965cbcca0accdb21
Publikováno v:
Biomedicines, Vol 11, Iss 11, p 2966 (2023)
Hepatitis B surface antigen (HBsAg) seroclearance, an indicator of recovery from hepatitis B virus (HBV) infection, is uncommon in long-term nucleos(t)ide analog (NUC) therapy. We compared the incidence of HBsAg seroclearance in patients with and wit
Externí odkaz:
https://doaj.org/article/48fcce2a7a124ab1b1b0cab9f1912c82
Autor:
Shun-Wen Hsiao, Ting-Chun Chen, Pei-Yuan Su, Chen-Ta Yang, Siou-Ping Huang, Yang-Yuan Chen, Hsu-Heng Yen
Publikováno v:
Diagnostics, Vol 13, Iss 20, p 3268 (2023)
The prevalence of inflammatory bowel disease (IBD) has increased worldwide. The prevalence of metabolic dysfunction associated fatty liver disease (MAFLD) has also risen. However, there is limited research on the connection between MAFLD and IBD in t
Externí odkaz:
https://doaj.org/article/853d9f19794a4d72b76eef5870d0f177
Autor:
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, Chun-Jen Liu, Ching-Chu Lo, Ke-Jhang Huang, Jyh-Jou Chen, Kuo-Chih Tseng, Chi-Yang Chang, Cheng-Yuan Peng, Yu-Lueng Shih, Chia-Sheng Huang, Wei-Yu Kao, Sheng-Shun Yang, Ming-Chang Tsai, Jo-Hsuan Wu, Po-Yueh Chen, Pei-Yuan Su, Jow-Jyh Hwang, Yu-Jen Fang, Pei-Lun Lee, Chi-Wei Tseng, Fu-Jen Lee, Hsueh-Chou Lai, Tsai-Yuan Hsieh, Chun-Chao Chang, Chung-Hsin Chang, Yi-Jie Huang, Jia-Horng Kao
Publikováno v:
Clinical and Molecular Hepatology, Vol 27, Iss 4, Pp 575-588 (2021)
Background/Aims Real-world studies assessing the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) plus ribavirin (RBV) for Child-Pugh B/C hepatitis C virus (HCV)-related cirrhosis are limited. Methods We included 107 patients with Child-P
Externí odkaz:
https://doaj.org/article/4ef4e404f00c418597db8898e8c2d587
Publikováno v:
PeerJ, Vol 10, p e14200 (2022)
Background A previous study reported a 30% prevalence of various autoantibodies among patients with hepatitis C virus (HCV) infection. The International Consensus on Anti-Nuclear Antibody (ANA) Patterns was recently introduced to classify ANA pattern
Externí odkaz:
https://doaj.org/article/1089fa94d6b4488497aa1cfb7c0f5166
Autor:
Hsu-Heng Yen, Pei-Yuan Su, I.-L.ing Liu, Ya-Huei Zeng, Siou-Ping Huang, Yu-Chun Hsu, Po-Ke Hsu, Yang-Yuan Chen
Publikováno v:
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-7 (2021)
Abstract Background Hepatitis C virus (HCV) is one of the major causes of chronic liver disease, cirrhosis, and liver cancer. Most of the infected people have no clinical symptoms. The current strategy for HCV elimination includes test and treatment.
Externí odkaz:
https://doaj.org/article/133452fe1d8d4790aa5a9cba340b5277
Publikováno v:
Diagnostics, Vol 13, Iss 8, p 1407 (2023)
The reported prevalence of non-alcoholic fatty liver disease in studies of lean individuals ranges from 7.6% to 19.3%. The aim of the study was to develop machine-learning models for the prediction of fatty liver disease in lean individuals. The pres
Externí odkaz:
https://doaj.org/article/4d3e0e0a971f4313a4673229e4fe0e2c
Publikováno v:
Biomedicines, Vol 11, Iss 3, p 752 (2023)
Chronic hepatitis B (CHB) relapse occurs after the cessation of nucleos(t)ide analogues (NUC) therapy due to the waning of viral suppression. Few studies have investigated the viral relapse rate and clinical relapse rate after tenofovir alafenamide (
Externí odkaz:
https://doaj.org/article/a7c78c5f64ee41319da731af5847b2df